A pair of peer-reviewed studies published in the New England Journal of Medicine are affirming the safety and effectiveness of Pfizer’s COVID-19 vaccine, first at six months following a completed, two-dose regimen, and then with boosters. The first study maintains that despite a gradual decline in efficacy, the Pfizer vaccine remains highly effective in preventing COVID-19, with efficacy declining approximately 6% every two months after an initial peak effectiveness of 96.2%. The authors further state that ongoing observations through two years following initial doses will determine the likely benefits of a booster program.

The second study, based out of Israel, found that a third, booster dose of the Pfizer vaccine yielded strong protections for individuals age 60 and older, with substantially lower rates of COVID-19 and severe illness. The authors state that, based on their review of available data, a booster dose for those age 60 and older “reduces the rate of infection for such vaccine recipients by a factor of 10.”

The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee will meet tomorrow to discuss Pfizer’s application for approval of a COVID-19 booster shot.
 

Related News Articles

Headline
The Agency for Healthcare Research and Quality seeks input through Nov. 12 on scientific evidence to inform a systematic review of telehealth use during…
Headline
The Centers for Disease Control and Prevention last week updated the list of underlying medical conditions that put adults of any age at higher risk for…
Chairperson's File
Working in health care delivery can be stressful and tiring under normal circumstances. And the COVID-19 pandemic has exerted incredible pressures on the…
Headline
The Department of Health and Human Services has renewed the COVID-19 public health emergency declaration for another 90 days effective Oct. 18. The extension…
Headline
The National Institutes of Health yesterday awarded a total of $78 million in funding to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2,…
Headline
Abbott Molecular Inc. yesterday issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and…